scholarly journals Oral Administration of an Immunostimulatory DNA Sequence fromBifidobacterium longumImproves Th1/Th2 Balance in a Murine Model

2006 ◽  
Vol 70 (8) ◽  
pp. 2013-2017 ◽  
Author(s):  
Noritoshi TAKAHASHI ◽  
Haruki KITAZAWA ◽  
Noriyuki IWABUCHI ◽  
Jin-Zhong XIAO ◽  
Kazuhiro MIYAJI ◽  
...  
Keyword(s):  
Oral Administration ◽  
Dna Sequence ◽  
Murine Model ◽  
Immunostimulatory Dna

Oral administration of Hsp65‐producing Lactococcus lactis attenuates allergic asthma in a murine model

2020 ◽  
Author(s):  
L.B. Lacerda ◽  
W.M. Rios ◽  
A.P. Masson ◽  
I.T. Brandão ◽  
T.M. Milani ◽  
...  
Keyword(s):  
Oral Administration ◽  
Allergic Asthma ◽  
Lactococcus Lactis ◽  
Murine Model

Oral Administration of IL-12 Suppresses Anaphylactic Reactions in a Murine Model of Peanut Hypersensitivity

2001 ◽  
Vol 101 (2) ◽  
pp. 220-228 ◽  
Author(s):  
Soo-Young Lee ◽  
Chih-Kang Huang ◽  
Teng-Fei Zhang ◽  
Brian H. Schofield ◽  
A.Wesley Burks ◽  
...  
Keyword(s):  
Oral Administration ◽  
Murine Model

scholarly journals Cytotoxic and Antitumoral Effects of Bikaverin from Gibberella fujikuroi on L5178Y Lymphoma Murine Model

2019 ◽  
Vol 63 (4) ◽  
Author(s):  
Gabriela Hinojosa Ventura ◽  
Ana María Puebla Pérez ◽  
Martha Patricia Gallegos Arreola ◽  
Ma del Carmen Chávez Parga ◽  
Antonio Romero Estrada ◽  
...  
Keyword(s):  
Nmr Spectroscopy ◽  
Oral Administration ◽  
Murine Model ◽  
Cytotoxic Effect ◽  
Antitumor Effect ◽  
Gibberella Fujikuroi ◽  
Tumor Evolution ◽  
Lymphoma Cells ◽  
Ic50 Value

In this work, bikaverin was isolated from the mycelium of Gibberella fujikuroi and characterized using 1D (1H and 13C) and 2D (HSQC and HMBC) NMR spectroscopy. Its cytotoxic effect on L5178Y lymphoma cells and antitumor effect on BALB/c mice inoculated with L5178Y cells were evaluated. According to the results, bikaverin showed cytotoxic effect against L5178Y lymphoma cells with an IC50 value of 0.23 μg/mL.The tumor evolution, with and without treatment, was observed in the in vivo study; the group without treatment showed 1,280±128 x 105 cells/mL in ascites volume, and the groups treated with bikaverin at the dose of 1.73 mg/kg/day by intraperitoneal (i.p.) and oral administration, decreased significantly the cell density, and showed 391.5±237 x 105 cells/mL and 580±208 x 105 cells/mL, respectively. The results confirm the cytotoxic effect of bikaverin on cancer cell lines and contribute to show the potential of bikaverin as antitumoral compound in BALB/c mice inoculated with L5178Y lymphoma cells.

scholarly journals Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom

Toxins ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 380 ◽  
Author(s):  
Matthew Lewin ◽  
José Gutiérrez ◽  
Stephen Samuel ◽  
María Herrera ◽  
Wendy Bryan-Quirós ◽  
...  
Keyword(s):  
Oral Administration ◽  
Phospholipase A2 ◽  
Murine Model ◽  
Unmet Need ◽  
Secretory Phospholipase A2 ◽  
Adjunct Treatment ◽  
Secretory Phospholipase ◽  
Heat Stable ◽  
Orally Bioavailable ◽  
Lethal Doses

There is an unmet need for economical snakebite therapies with long shelf lives that are effective even with delays in treatment. The orally bioavailable, heat-stable, secretory phospholipase A2 (sPLA2) inhibitor, LY333013, demonstrates antidotal characteristics for severe snakebite envenoming in both field and hospital use. A murine model of lethal envenoming by a Papuan taipan (Oxyuranus scutellatus) demonstrates that LY333013, even with delayed oral administration, improves the chances of survival. Furthermore, LY333013 improves the performance of antivenom even after it no longer reverses neurotoxic signs. Our study is the first demonstration that neurotoxicity from presynaptic venom sPLA2S can be treated successfully, even after the window of therapeutic antivenom has closed. These results suggest that sPLA2 inhibitors have the potential to reduce death and disability and should be considered for the initial and adjunct treatment of snakebite envenoming. The scope and capacity of the sPLA2 inhibitors ability to achieve these endpoints requires further investigation and development efforts.

Oral Administration of a Cholera Vaccine Antigen Facilitates Colonic Mucosal Healing in a Murine Model of Colitis

2017 ◽  
Vol 152 (5) ◽  
pp. S572-S573
Author(s):  
Joshua M. Royal ◽  
Keegan Baldauf ◽  
Kavitha Yaddanapudi ◽  
Gerald W. Dryden ◽  
Nobuyuki Matoba
Keyword(s):  
Oral Administration ◽  
Murine Model ◽  
Mucosal Healing ◽  
Vaccine Antigen ◽  
Cholera Vaccine
Sign in / Sign up

Export Citation Format

Share Document